Author

F. Kuttler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 2 Assay:imaging· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

G. Turcatti· 3 shared U. F. Greber· 3 shared V. Andriasyan· 3 shared A. Yakimovich· 2 shared F. Georgi· 2 shared L. Murer· 2 shared N. Meili· 2 shared R. Witte· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

G. Turcatti

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Repression of Aurora kinase B prevents growth and tissue invasion in medulloblastoma

A. Gries, K. Santhana Kumar, F. Kuttler, M. A. Grotzer, M. Baumgartner

This study identifies AURKB as a therapeutic target in medulloblastoma, showing that its inhibition in the tissue context effectively restricts tumor growth and invasiveness, comparable to irradiation.

bioRxiv · Jun 23, 2023 · PreprintCancer Biology

Arrayed multicycle drug screens identify broadly acting chemical inhibitors for repurposing against SARS CoV 2

L. P. Murer, R. Volle, V. Andriasyan, N. Meili, L. Yang, D. Sequeira, A. Gomez-Gonzalez, A. Petkidis, D. Olszewski, M. Bauer, M. Suomalainen, F. Kuttler, G. Turcatti, U. F. Greber

The paper screens 5440 compounds to identify chemical inhibitors effective against multiple coronaviruses, including SARS-CoV-2, finding several FDA-approved drugs with potential for repurposing.

bioRxiv · Mar 30, 2021 · PreprintMicrobiology

The FDA-approved drug Nelfinavir inhibits lytic cell-free transmission of human adenoviruses

F. Georgi, V. Andriasyan, R. Witte, L. Murer, S. Hemmi, L. Yu, M. Grove, N. Meili, F. Kuttler, A. Yakimovich, G. Turcatti, U. F. Greber

This paper shows that the FDA-approved drug Nelfinavir inhibits lytic cell-free transmission of certain human adenoviruses but not non-lytic transmission.

bioRxiv · May 15, 2020Microbiology

High-content image-based drug screen identifies a clinical compound against cell transmission of adenovirus

F. Georgi, F. Kuttler, L. Murer, V. Andriasyan, R. Witte, A. Yakimovich, G. Turcatti, U. F. Greber

The paper identifies Nelfinavir mesylate as an inhibitor of adenovirus multi-round plaque formation using an image-based high-throughput screening platform.

bioRxiv · Mar 24, 2020Microbiology